Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Oncología >
DA - CIMA - Oncología - Biomarcadores - Artículos de Revista >
|Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates|
|Authors: ||Warren, K.E. (Katherine E.)|
Patel, M.C. (Mahendra C.)
McCully, C.M. (Cynthia M.)
Montuenga, L.M. (Luis M.)
Balis, F.M. (Frank M.)
|Keywords: ||Multidrug resistance|
|Issue Date: ||2000|
|Publisher: ||Springer Verlag|
|Publisher version: ||http://www.springerlink.com/content/yc56xpnt3w7v9a7p/|
|Citation: ||Warren KE, Patel MC, McCully CM, Montuenga LM, Balis FM. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Cancer Chemother Pharmacol 2000;45(3):207-212.|
P-glycoprotein (Pgp) is a transmembrane drug efflux pump that is expressed in multidrug-resistant cancer cells and in a variety of normal tissues, including brain capillary endothelial cells which comprise the blood-brain barrier. We studied the effects of the Pgp inhibitor, cyclosporin A (CsA), on the cerebrospinal fluid (CSF) penetration of the Pgp substrate, doxorubicin, in non-human primates.
The animals received doxorubicin alone (2.0 mg/kg i.v. over 60 min) or doxorubicin (1 mg/kg i.v. over 60 min) and CsA (loading dose 4.0 mg/kg i.v. over 2 h, followed by continuous infusion of 12 mg/kg per day over 48 h). Plasma and CSF were collected over 48 h and the doxorubicin concentration was measured by reverse-phase high-pressure liquid chromatography (HPLC) with fluorescence detection (detection limit 5 nM). A two-compartment model was fitted to the plasma concentration-time data.
Pgp was demonstrated to be present in the epithelium of the choroid plexus by immunohistochemical methods, indicating that CSF drug penetration could be used as a surrogate for blood-brain barrier penetration. Steady state whole blood CsA concentrations, which were measured with a fluorescence-polarization immunoassay (TDX) that detects both CsA and its metabolites, ranged from 551-1315 microg/l at 24 h. The clearance of doxorubicin in four animals was reduced by 34%, 38%, 45% and 49% when given with CsA. The doxorubicin concentration in the CSF was <5 nM in all animals, both after doxorubicin alone and doxorubicin with CsA.
The Pgp inhibitor, CsA, at a concentration that alters systemic clearance of doxorubicin, does not appear to significantly increase the CSF penetration of doxorubicin.
|Permanent link: ||http://hdl.handle.net/10171/20174|
|Appears in Collections:||DA - Ciencias - HAP - Artículos de revista|
DA - CIMA - Oncología - Biomarcadores - Artículos de Revista
|Files in This Item:|
||38KEWarren et al_CancerChemotherPharmacol00.pdf|
| View / Open |
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.